The Fly
Super Micro downgraded, MongoDB upgraded: Wall Street's top analyst calls
📈
AI Sentiment
Highly Positive
8/10
- Home
- ZBH
as of 03-24-2026 3:52pm EST
$86.09
$1.72
-1.95%
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
| Founded: | 1927 | Country: | United States |
| Employees: | N/A | City: | WARSAW |
| Market Cap: | 19.5B | IPO Year: | 2001 |
| Target Price: | $104.76 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Hold | Number of Analysts: | 19 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 3.55 | EPS Growth: | -19.86 |
| 52 Week Low/High: | $84.59 - $114.44 | Next Earning Date: | 05-04-2026 |
| Revenue: | $8,231,500,000 | Revenue Growth: | 7.20% |
| Revenue Growth (this year): | 4.93% | Revenue Growth (next year): | 3.72% |
| P/E Ratio: | 24.88 | Index: | |
| Free Cash Flow: | 1.5B | FCF Growth: | +11.07% |
Stock Insider Trading Activity of Zimmer Biomet Holdings Inc. (ZBH)
Winkler Lori
Sell
SVP and CHRO
ZBH Mar 12, 2026
Avg Cost/Share
$94.66
Shares
2,650
Total Value
$250,849.00
Owned After
10,224
SEC Form 4
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 10, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 10, 2026 · 100% conf.
AI Prediction BUY
1D
+0.63%
$91.98
Act: +4.61%
5D
+2.95%
$94.10
Act: +7.49%
20D
+3.16%
$94.29
Price: $91.40 Prob +5D: 100% AUC: 1.000
0001193125-26-043620
8-K
0001136869false0001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2026-02-102026-02-1000011368692026-02-102026-02-100001136869us-gaap:CommonStockMember2026-02-102026-02-100001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2026-02-102026-02-100001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2026-02-102026-02-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 10, 2026
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-16407
13-4151777
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
345 East Main Street
Warsaw, Indiana
46580
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (574) 373-3333
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
ZBH
New York Stock Exchange
2.425% Notes due 2026
ZBH 26
New York Stock Exchange
1.164% Notes due 2027
ZBH 27
New York Stock Exchange
3.518% Notes due 2032
ZBH 32
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2026, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.
The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated February 10, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 10, 2026
ZIMMER BIOMET HOLDINGS, INC.
By:
/s/ Chad F. Phipps
Name:
Chad F. Phipps
Title:
Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary
2025 Q3 Q3 2025 Earnings
8-K Nov 5, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 5, 2025
0001193125-25-265649
8-K
false00011368690001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2025-11-052025-11-050001136869us-gaap:CommonStockMember2025-11-052025-11-0500011368692025-11-052025-11-050001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2025-11-052025-11-050001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2025-11-052025-11-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 5, 2025
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-16407
13-4151777
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
345 East Main Street
Warsaw, Indiana
46580
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (574) 373-3333
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
ZBH
New York Stock Exchange
2.425% Notes due 2026
ZBH 26
New York Stock Exchange
1.164% Notes due 2027
ZBH 27
New York Stock Exchange
3.518% Notes due 2032
ZBH 32
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.
The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated November 5, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 5, 2025
ZIMMER BIOMET HOLDINGS, INC.
By:
/s/ Chad F. Phipps
Name:
Chad F. Phipps
Title:
Senior Vice President, General Counsel and Secretary
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0000950170-25-104527
8-K
false00011368690001136869zbh:OnePointOneSixFourPercentageNotesDueTwoThousandTwentySevenMember2025-08-072025-08-0700011368692025-08-072025-08-070001136869zbh:TwoPointFourTwoFivePercentageNotesDueTwoThousandTwentySixMember2025-08-072025-08-070001136869us-gaap:CommonStockMember2025-08-072025-08-070001136869zbh:ThreePointFiveOneEightPercentageNotesDueTwoThousandThirtyTwoMember2025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 7, 2025
ZIMMER BIOMET HOLDINGS, INC.
(Exact name of Registrant as Specified in Its Charter)
Delaware
001-16407
13-4151777
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
345 East Main Street
Warsaw, Indiana
46580
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (574) 373-3333
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
ZBH
New York Stock Exchange
2.425% Notes due 2026
ZBH 26
New York Stock Exchange
1.164% Notes due 2027
ZBH 27
New York Stock Exchange
3.518% Notes due 2032
ZBH 32
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 7, 2025, Zimmer Biomet Holdings, Inc. (the “Company”) issued a press release reporting its financial results for the quarter ended June 30, 2025. A copy of the press release is attached as Exhibit 99.1 and the information set forth therein is incorporated herein by reference and constitutes a part of this report.
The information contained in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press release dated August 7, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2025
ZIMMER BIOMET HOLDINGS, INC.
By:
/s/ Chad F. Phipps
Name:
Chad F. Phipps
Title:
Senior Vice President, General Counsel and Secretary
Latest Zimmer Biomet Holdings Inc. News
ZBH Breaking Stock News: Dive into ZBH Ticker-Specific Updates for Smart Investing
Motley Fool
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
➖
AI Sentiment
Neutral
4/10
StockStory
Surgical Equipment & Consumables - Diversified Stocks Q4 In Review: Zimmer Biomet (NYSE:ZBH) Vs Peers
➖
AI Sentiment
Neutral
4/10
Compare ZBH vs Leading Stocks
See how ZBH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ZBH Zimmer Biomet Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.